Dosage regimen for picotamide for the use in migraine
US11166946B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 18, 2020 |
| Grant date | Nov 9, 2021 |
| Priority date | — |
| Expiry date | Nov 18, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Picotamide (4-methoxy-N,N′-bis(pyridin-3-ylmethyl)benzene-1,3-dicarboxamide, CAS-no. 32828-81-2) can be used in the treatment and/or prevention of migraine with aura. A specific dosage regimen is used in this treatment and/or prevention, where, in a first period, picotamide is administered for 2 to 6 months, and the first period is followed by a second period of 1 to 3 months without picotamide administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.